BlackRock’s INmune Bio INMB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $508K | Sell |
311,613
-882,499
| -74% | -$1.22M | ﹤0.01% | 4577 |
|
|
2026
Q1 | $1.35M | Sell |
1,194,112
-17,988
| -1% | -$25.6K | ﹤0.01% | 4242 |
|
|
2025
Q4 | $1.89M | Buy |
1,212,100
+25,224
| +2% | +$45K | ﹤0.01% | 4129 |
|
|
2025
Q3 | $2.46M | Buy |
1,186,876
+14,435
| +1% | +$33K | ﹤0.01% | 4028 |
|
|
2025
Q2 | $2.71M | Buy |
1,172,441
+224,079
| +24% | +$1.64M | ﹤0.01% | 3980 |
|
|
2025
Q1 | $7.41M | Sell |
948,362
-41,196
| -4% | -$327K | ﹤0.01% | 3468 |
|
|
2024
Q4 | $4.62M | Buy |
989,558
+50,090
| +5% | +$261K | ﹤0.01% | 3760 |
|
|
2024
Q3 | $5.06M | Buy |
939,468
+126,573
| +16% | +$900K | ﹤0.01% | 3692 |
|
|
2024
Q2 | $7.17M | Buy |
812,895
+572,729
| +238% | +$5.65M | ﹤0.01% | 3554 |
|
|
2024
Q1 | $2.82M | Sell |
240,166
-17,763
| -7% | -$215K | ﹤0.01% | 3876 |
|
|
2023
Q4 | $2.9M | Buy |
257,929
+25,105
| +11% | +$210K | ﹤0.01% | 3898 |
|
|
2023
Q3 | $1.58M | Sell |
232,824
-6,809
| -3% | -$56.5K | ﹤0.01% | 4088 |
|
|
2023
Q2 | $2.18M | Buy |
239,633
+4,909
| +2% | +$39.4K | ﹤0.01% | 4020 |
|
|
2023
Q1 | $1.52M | Sell |
234,724
-601
| -0.3% | -$4.84K | ﹤0.01% | 4177 |
|
|
2022
Q4 | $1.49M | Buy |
235,325
+2,082
| +0.9% | +$14.8K | ﹤0.01% | 4256 |
|
|
2022
Q3 | $1.45M | Sell |
233,243
-877
| -0.4% | -$7.7K | ﹤0.01% | 4344 |
|
|
2022
Q2 | $2.07M | Buy |
234,120
+2,121
| +0.9% | +$15.8K | ﹤0.01% | 4241 |
|
|
2022
Q1 | $1.95M | Sell |
231,999
-1,266
| -0.5% | -$11.4K | ﹤0.01% | 4407 |
|
|
2021
Q4 | $2.38M | Buy |
233,265
+86,836
| +59% | +$1.29M | ﹤0.01% | 4338 |
|
|
2021
Q3 | $2.84M | Sell |
146,429
-37,577
| -20% | -$726K | ﹤0.01% | 4170 |
|
|
2021
Q2 | $3.23M | Sell |
184,006
-35,724
| -16% | -$481K | ﹤0.01% | 4065 |
|
|
2021
Q1 | $2.61M | Buy |
219,730
+198,487
| +934% | +$3.57M | ﹤0.01% | 4207 |
|
|
2020
Q4 | $366K | Buy |
21,243
+2,854
| +16% | +$26.9K | ﹤0.01% | 4391 |
|
|
2020
Q3 | $190K | Sell |
18,389
-413
| -2% | -$4.2K | ﹤0.01% | 4419 |
|
|
2020
Q2 | $98K | Buy |
18,802
+3,050
| +19% | +$15.4K | ﹤0.01% | 4492 |
|
|
2020
Q1 | $52K | Buy |
15,752
+9,200
| +140% | +$41.6K | ﹤0.01% | 4463 |
|
|
2019
Q4 | $38K | Buy |
6,552
+2,597
| +66% | +$12.5K | ﹤0.01% | 4572 |
|
|
2019
Q3 | $24K | Buy |
3,955
+907
| +30% | +$6.71K | ﹤0.01% | 4626 |
|
|
2019
Q2 | $29K | Buy |
3,048
+2,864
| +1,557% | +$29K | ﹤0.01% | 4640 |
|
|
2019
Q1 | $1K | Buy |
+184
| New | +$1.42K | ﹤0.01% | 4875 |
|
Other funds holding INMB
WIM
BlackRock's INMB Position: Q2 2026 in Review
BlackRock reduced its INmune Bio (INMB) stake by 74% in Q2 2026, selling an estimated $1.22M and leaving 311,613 shares worth $508K. The position accounts for ﹤0.01% of the portfolio, ranked #4577.
BlackRock first reported a position in INMB in Q1 2019 and has held it in 30 quarters since. The position peaked at $7.41M in Q1 2025. 83 funds tracked by Wall St. Rank hold INMB as of Q2 2026.
- BlackRock held 311,613 shares of INmune Bio worth $508K as of Q2 2026.
- BlackRock sold 882,499 INmune Bio shares in Q2 2026, an estimated $1.22M.
- INmune Bio made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4577 holding.
- BlackRock first reported a position in INmune Bio in Q1 2019 and has held it in 30 quarters since.
- BlackRock's INmune Bio position peaked at $7.41M in Q1 2025.
- 83 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.